James R. Kasinger - 13 Oct 2025 Form 4 Insider Report for CRISPR Therapeutics AG (CRSP)

Role
General Counsel and Secretary
Signature
/s/ Elizabeth Ryland Waldinger, attorney-in-fact
Issuer symbol
CRSP
Transactions as of
13 Oct 2025
Transactions value $
-$71,662
Form type
4
Filing time
15 Oct 2025, 17:35:03 UTC
Previous filing
03 Oct 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
KASINGER JAMES R. General Counsel and Secretary C/O CRISPR THERAPEUTICS, 105 WEST FIRST STREET, BOSTON /s/ Elizabeth Ryland Waldinger, attorney-in-fact 15 Oct 2025 0001708172

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRSP Common Shares Options Exercise +2.11K +2.57% 84.5K 13 Oct 2025 Direct F1, F2
transaction CRSP Common Shares Sale -$71.7K -1.08K -1.27% $66.60 83.4K 14 Oct 2025 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRSP Restricted Stock Units Options Exercise -2.11K -50.01% 2.11K 13 Oct 2025 Common Shares 2.11K Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
F2 Includes 635 shares acquired under the CRISPR Therapeutics AG 2016 Employee Stock Purchase Plan.
F3 Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.
F4 This restricted stock unit award was granted on October 13, 2023 with respect to 6,340 Common Shares, with (i) one third of the shares vesting on October 13, 2024, (ii) one third of the shares vesting on October 13, 2025, and (iii) one third of the shares vesting on October 13, 2026.